https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-to-present-at-biotech-showcasetm-2022-2022-01-04
https://www.nasdaq.com/press-release/fda-authorizes-further-nurownr-dosing-under-expanded-access-program-2021-12-27
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-announces-peer-reviewed-publication-of-nurownsr-phase-3
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-and-catalent-announce-completion-of-technology-transfer
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-to-present-new-biomarker-data-on-nurownr-at-the
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-announces-the-presentation-of-new-analyses-from-the
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-announces-third-quarter-2021-financial-results-and
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-expands-leadership-team-to-support-clinical-development
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-announces-appointment-of-menghis-bairu-md-to-board-of
https://www.nasdaq.com/press-release/brainstorm-to-announce-third-quarter-financial-results-and-provide-a-corporate-update
https://www.nasdaq.com/press-release/brainstorm-announces-scientific-presentation-of-nurownr-exosome-preclinical-ards-0
https://www.nasdaq.com/press-release/phase-2-clinical-trial-data-of-nurownr-in-progressive-ms-will-be-presented-at-the
https://www.nasdaq.com/press-release/brainstorm-to-present-als-phase-3-biomarker-analyses-at-annual-neals-meeting-october
https://www.nasdaq.com/press-release/brainstorm-to-present-at-the-2021-cell-gene-meeting-on-the-mesa-2021-10-04
https://www.nasdaq.com/press-release/brainstorm-to-present-phase-2-progressive-ms-study-results-in-oral-presentation-at
https://www.nasdaq.com/press-release/brainstorm-announces-second-quarter-2021-financial-results-and-provides-a-corporate
https://www.nasdaq.com/press-release/brainstorm-increases-commercial-manufacturing-capacity-granted-gmp-certification-for
https://www.nasdaq.com/press-release/brainstorm-to-announce-second-quarter-financial-results-and-provide-a-corporate
https://www.nasdaq.com/press-release/brainstorm-announces-expansion-of-nurownr-ip-portfolio-with-grant-and-allowance-of
https://www.nasdaq.com/press-release/brainstorm-announces-scientific-presentation-of-nurownr-exosome-preclinical-ards-data
https://www.nasdaq.com/press-release/brainstorm-announces-first-quarter-2021-financial-results-and-provides-a-corporate
https://www.nasdaq.com/press-release/brainstorm-to-announce-first-quarter-financial-results-and-provide-a-corporate-update
https://www.nasdaq.com/press-release/brainstorm-announces-positive-topline-data-in-phase-2-study-evaluating-nurownr-as-a
https://www.nasdaq.com/press-release/brainstorm-to-present-at-svb-leerink-10th-global-healthcare-conference-2021-02-23
https://www.nasdaq.com/press-release/brainstorm-announces-high-level-fda-feedback-on-nurownr-als-clinical-development
https://www.nasdaq.com/press-release/brainstorm-announces-feedback-from-fda-type-c-meeting-on-future-nurownr-manufacturing
https://www.nasdaq.com/press-release/brainstorm-announces-full-year-2020-financial-results-and-provides-a-corporate-update
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-to-announce-fourth-quarter-and-fiscal-year-2020
https://www.nasdaq.com/press-release/brainstorm-announces-the-publication-of-preclinical-data-highlighting-the-potential
https://www.nasdaq.com/press-release/brainstorm-issues-2020-letter-to-shareholders-2020-12-28
https://www.nasdaq.com/press-release/brainstorm-announces-completion-of-all-dosing-in-nurownr-phase-2-ms-study-2020-12-18
https://www.nasdaq.com/press-release/brainstorm-announces-nurownr-expanded-access-program-2020-12-14
https://www.nasdaq.com/press-release/brainstorm-to-present-nurownr-phase-3-clinical-trial-results-at-31st-international
https://www.nasdaq.com/press-release/brainstorm-announces-topline-results-from-nurownr-phase-3-als-study-2020-11-17
https://www.nasdaq.com/press-release/rapid-reshore-development-and-brainstorm-cell-therapeutics-announce-agreement-to
https://www.nasdaq.com/press-release/catalent-and-brainstorm-cell-therapeutics-announce-partnership-for-the-manufacture-of
https://www.nasdaq.com/press-release/catalent-and-brainstorm-cell-therapeutics-announce-partnership-for-the-manufacture-0
https://www.nasdaq.com/press-release/brainstorm-announces-scientific-presentation-of-nurownr-exosome-preclinical-ards
https://www.nasdaq.com/press-release/brainstorm-announces-financial-results-for-the-third-quarter-of-2020-and-provides-a
https://www.nasdaq.com/press-release/brainstorm-to-present-at-the-2020-cell-gene-meeting-on-the-mesa-2020-10-12
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-to-announce-third-quarter-financial-results-and-0
https://www.nasdaq.com/press-release/brainstorm-announces-scientific-presentation-at-the-annual-neals-meeting-2020-09-30
https://www.nasdaq.com/press-release/brainstorm-appoints-william-k.-white-as-senior-vice-president-head-of-market-access
https://www.nasdaq.com/press-release/brainstorm-announces-grant-of-a-new-japanese-patent-for-nurownr-2020-09-16
https://www.nasdaq.com/press-release/brainstorm-to-present-at-scientific-conferences-in-september-2020-09-03
https://www.nasdaq.com/press-release/brainstorm-appoints-pharmaceutical-veteran-anthony-waclawski-as-executive-vice
https://www.nasdaq.com/press-release/brainstorm-to-present-data-linking-mri-measures-to-functional-improvement-in
https://www.nasdaq.com/press-release/brainstorm-announces-publication-of-new-preclinical-data-supporting-proposed-nurownr
https://www.nasdaq.com/press-release/brainstorm-to-present-at-the-40th-annual-canaccord-genuity-growth-conference-2020-08
https://www.nasdaq.com/press-release/brainstorm-announces-financial-results-for-the-second-quarter-of-2020-and-provides-a
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-to-announce-second-quarter-financial-results-and-provide
https://www.nasdaq.com/press-release/brainstorm-announces-groundbreaking-pre-clinical-study-of-nurownr-derived-exosome
https://www.nasdaq.com/press-release/brainstorm-hosting-kol-webinar-to-discuss-nurownr-phase-2-alzheimers-disease-program
https://www.nasdaq.com/press-release/brainstorm-announces-completion-of-all-dosing-in-nurownr-phase-3-clinical-trial-in
https://www.nasdaq.com/press-release/brainstorm-to-showcase-alzheimers-disease-clinical-program-in-kol-webinar-2020-07-01
https://www.nasdaq.com/press-release/brainstorm-expands-clinical-pipeline-to-evaluate-nurownr-for-the-treatment-of
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-to-join-the-russell-2000r-index-and-russell-3000r-index
https://www.nasdaq.com/press-release/brainstorm-granted-sme-status-by-the-european-medicines-agency-2020-06-15
https://www.nasdaq.com/press-release/brainstorm-to-present-at-the-raymond-james-human-health-innovations-conference-2020
https://www.nasdaq.com/press-release/the-als-association-i-am-als-award-brainstorm-cell-therapeutics-%24500000-for-als
https://www.nasdaq.com/press-release/brainstorm-to-participate-in-bio-digital-2020-2020-06-03
https://www.nasdaq.com/press-release/brainstorm-announces-that-pivotal-phase-3-trial-remains-on-track-for-topline-data-in
https://www.nasdaq.com/press-release/brainstorm-appoints-pharmaceutical-veteran-stacy-r.-lindborg-ph.d.-as-executive-vice
https://www.nasdaq.com/press-release/brainstorm-announces-financial-results-for-the-first-quarter-of-2020-and-provides-a
https://www.nasdaq.com/press-release/brainstorm-leases-a-new-cleanroom-facility-at-the-tel-aviv-sourasky-medical-center-to
https://www.nasdaq.com/press-release/brainstorm-presents-new-data-highlighting-nurownr-immunomodulation-in-neurology-2020
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-to-announce-first-quarter-financial-results-and-provide
https://www.nasdaq.com/press-release/brainstorm-awarded-%241.5-million-non-dilutive-grant-for-2020-by-the-israel-innovation
https://www.nasdaq.com/press-release/david-setboun-joins-brainstorm-as-executive-vice-president-and-chief-operating
https://www.nasdaq.com/press-release/brainstorm-appoints-renowned-distinguished-economist-prof.-jacob-frenkel-chairman-of
https://www.nasdaq.com/press-release/brainstorm-to-hold-a-conference-call-to-update-investors-on-corporate-steps-taken-to
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-raises-%2410.0-million-in-common-stock-sale-at-%248.00-per
https://www.nasdaq.com/press-release/fifth-and-final-site-announced-for-brainstorms-progressive-multiple-sclerosis-phase-2
https://www.nasdaq.com/press-release/brainstorm-announces-operational-highlights-and-financial-results-for-the-year-ended
https://www.nasdaq.com/press-release/brainstorms-chief-operating-officer-to-present-at-noble-capital-markets-sixteenth
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-and-fda-agree-to-potential-nurownr-regulatory-pathway
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-to-announce-fourth-quarter-and-full-year-2019-financial
https://www.nasdaq.com/press-release/brainstorm-ceo-to-provide-company-update-at-the-bio-ceo-investor-conference-2020-02
https://www.nasdaq.com/press-release/brainstorm-receives-notice-of-intention-to-grant-additional-eu-patent-for-nurownr
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-coo-and-cmo-dr.-ralph-kern-to-present-at-the-10th-annual
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-to-present-at-the-2020-biotech-showcase-and-3rd-annual
https://www.nasdaq.com/press-release/nurownr-data-safety-monitoring-board-recommends-ms-phase-2-clinical-trial-continue
https://www.nasdaq.com/press-release/brainstorm-issues-2019-letter-to-shareholders-2019-12-18
https://www.nasdaq.com/press-release/brainstorm-selected-as-buzz-of-bio-2020-winner-2019-12-11
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-to-make-scientific-presentations-at-the-30th
https://www.nasdaq.com/press-release/brainstorm-announces-the-mount-sinai-medical-center-as-a-progressive-ms-phase-2
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-announces-publication-of-nurownr-als-phase-2-randomized
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-announces-research-grant-award-from-the-national
https://www.nasdaq.com/press-release/brainstorm-announces-financial-results-for-the-third-quarter-of-2019-and-provides-a
https://www.nasdaq.com/press-release/brainstorm-announces-grant-of-a-new-japanese-patent-for-nurownr-2019-11-13
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-announces-ralph-kern-md-mhsc-to-present-at-the-7th
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-to-announce-third-quarter-financial-results-and-provide
https://www.nasdaq.com/press-release/nurownr-data-safety-monitoring-board-recommends-als-phase-3-clinical-trial-continue
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-to-present-at-the-dawson-james-securities-5th-annual
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-president-and-ceo-to-be-featured-as-keynote-speaker-at
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-presentations-at-neuromuscular-drug-development-summit
https://www.nasdaq.com/press-release/brainstorms-nurownr-phase-3-als-clinical-trial-now-fully-enrolled-2019-10-11
https://www.nasdaq.com/press-release/brainstorm-announces-notice-of-us-patent-allowance-for-nurownr-cellular-therapeutic
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-to-present-nurownr-phase-2-biomarker-data-at-north-east
https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-announces-support-for-fda-guidelines-on-als-drug
